Archive | Clinical Trials

BMS’ Opdivo plus Yervoy misses the mark in high-risk melanoma

Bristol Myers Squibb has revealed some underwhelming results for its immunotherapy combination treatment Opdivo plus Yervoy in resected high-risk melanoma patients.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

CheckMate-915 Trial Does Not Meet Co-Primary End Point of RFS for Melanoma

Updated results from the randomized, phase 3 CheckMate-915 trial found that nivolumab (Opdivo) plus ipilimumab (Yervoy) did not result in a statistically significant improvement in recurrence-free survival (RFS) in the intention-to-treat population of participants, according to Bristol Myers Squibb, the developer of the agents.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Dr. Shoushtari on the Rationale for the CheckMate-067 Trial in Advanced Melanoma

Alexander N. Shoushtari, MD, an assistant attending physician at Memorial Sloan Kettering Cancer Center, discusses the rationale for the ?phase 3 CheckMate-067 trial in advanced melanoma.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials

Five-Year Outcomes: First-Line Nivolumab vs Dacarbazine in Advanced BRAF Wild-Type Melanoma

The 5-year outcomes of the CheckMate 066 trial, reported in the Journal of Clinical Oncology by Caroline Robert, MD, PhD, and colleagues, showed continued benefit of first-line nivolumab vs dacarbazine in advanced BRAF wild-type melanoma. The results add to data indicating that nivolumab can be associated with long-term survival in this setting.

Read the full story

Posted in Melanoma News, Health Professionals, Clinical Trials